Candida Parapsilosis + Krusei IgG

Use this test narrowly. The evidence behind Candida antibody testing comes mostly from hospitalized people with suspected invasive candidiasis, not from healthy people screening for yeast overgrowth.

This test measures serum IgG against Candida parapsilosis and Candida krusei. Serum comes from a blood draw. IgG can last after an infection or exposure, so the result is a clue about immune response, not a direct measurement of live yeast.

What This Test Actually Measures

The marker is IgG aimed at a combined Candida parapsilosis plus krusei target. The lab is looking for your antibody response to these yeasts, not the yeast itself.

No universal clinical cutpoints exist for this exact commercial result. Each lab has to validate its own positive, negative, or equivocal categories. That matters because a number from one assay may not mean the same thing as a number from another.

What the Evidence Actually Measures

Most published accuracy studies measured serum anti-mannan IgG, Candida albicans germ-tube antibody, or IgG against Candida proteins such as enolase, Fba1, Als3, and Mp65. Those are related antibody tests, but they are not the same as this combined Candida parapsilosis plus krusei IgG result.

So the numbers from those studies should be read as evidence about Candida antibody testing as a class. They do not validate this exact assay as a stand-alone diagnostic test.

The Infection It Can Point Toward

The serious disease behind this kind of result is invasive candidiasis, especially candidemia. That means Candida has reached the bloodstream or another normally sterile part of the body. Mortality is often around 40 percent, partly because the people who get it are usually already very sick.

The risk pattern is hospital-shaped: central lines, intensive care, major surgery, parenteral nutrition, diabetes, transplant drugs, chemotherapy, and other immune-suppressing states. C. parapsilosis is especially tied to catheters and plastic devices. C. krusei naturally resists fluconazole.

Why the Species Name Can Mislead

This result combines Candida parapsilosis and Candida krusei, so it should not be read as a clean species call. A positive result says your immune system reacted to the target mix.

Older serum antigen research shows why species labels can blur. In one 197-patient study, a C. krusei mannan signal appeared in 10 people with C. parapsilosis, 2 with C. guilliermondii, and only 1 with C. krusei. That was an antigen assay, not this IgG test, but it makes the same point: Candida assays can cross-react.

How It Compares With Better-Validated Tests

A positive blood culture remains the firmest proof because it grows the organism and allows drug susceptibility testing. The problem is speed and sensitivity. Blood culture takes about two to five days and misses many invasive cases.

Related serum mannan plus anti-mannan testing has pooled sensitivity around 83 percent and specificity around 86 percent in reviews. Anti-mannan IgG alone performs worse. PCR on serum and T2Candida on whole blood have shown faster, higher-sensitivity results in selected studies, but those tests look for Candida genetic material directly. They are not antibody tests.

IgG, Timing, and Immune Status

IgG is usually a later and longer-lasting antibody signal. That makes it useful in some settings, but it also makes timing hard. A positive result can trail behind the event that triggered it.

A weak immune system can do the opposite and blunt the signal. Neutropenia, blood cancers, transplant drugs, high-dose steroids, and some chemotherapy can make antibody tests falsely quiet even when infection is present.

A Higher Level Is Not a Severity Score

More Candida IgG does not always mean worse infection. In one study of 92 people with candidemia, higher IgG against two Candida proteins was linked with better 30-day survival. That study measured Als3 and Mp65 IgG, not this exact test, but it shows why Candida IgG should not be read as a simple good-number-bad-number dial.

When Results Can Be Misleading

• Different assay target: published performance numbers often come from anti-mannan, germ-tube antibody, or recombinant-protein IgG tests, not this exact Candida parapsilosis plus krusei IgG assay.
• Past exposure: Candida can live harmlessly on skin and in the gut, and IgG can persist after exposure.
• Colonization: recent ICU data show that Candida colonization alone can raise anti-Candida antibody levels, which is one reason a positive result in a well person is hard to interpret.
• Species blur: a combined parapsilosis plus krusei result cannot tell you which species caused the antibody response.
• Weak antibody production: immune-suppressing drugs and severe immune weakness can give a falsely low or negative antibody result.
• False positives from other infections: in one related anti-mannan IgG study, about a quarter of people with bacterial bloodstream infection tested positive, including all four with Pseudomonas bacteremia.
• Companion-test blind spots: beta-D-glucan can miss C. parapsilosis more often than some other Candida species, while C. krusei tends to be easier for beta-D-glucan to detect.

How to Read It

A Candida parapsilosis plus krusei IgG result is useful only in context. It gains weight when you also have fever, sepsis, a central line, recent intensive care, immune suppression, or matching evidence from culture, beta-D-glucan, mannan testing, or a molecular test.

If you feel well and this showed up on a broad panel, the most likely explanation is past exposure, harmless colonization, or cross-reactivity. A lone IgG result does not justify antifungal treatment.